3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, Large-Cell, Anaplastic
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
22
fludarabine
20
venetoclax
8
Whole-Body Irradiation
8
Mycophenolic Acid
8
Standard of Care
6
Mesna
6
Melphalan
6
Azacitidine
6
fludarabine phosphate
5
Sirolimus
5
thymoglobulin
4
Thiotepa
4
Tacrolimus
4
Specimen Handling
4
Filgrastim
4
Cytarabine
4
entrectinib
3
daratumumab
3
cobimetinib
3
alectinib
3
Vemurafenib
3
Surveys and Questionnaires
3
Rituximab
3
Practice Guidelines as Topic
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
Bortezomib
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Neoplasms
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT07036133
2026-02-11
SPI-FOL-102
Acrotech Biopharma Inc.
Phase 1
Recruiting
24 enrolled